Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Mutations of the RAS oncogene are found in around 30% of all human cancers yet direct
targeting of RAS is still considered clinically impractical except for the KRASG12C mutant …

Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into
small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common …

Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this,
there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar …

We address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in
KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR …

Mutations in ERK signaling drive a significant percentage of malignancies. LY3009120, a
pan-RAF and dimer inhibitor, has preclinical activity in RAS-and BRAF-mutated cell lines …